Sivik Global Healthcare LLC Invests $5.59 Million in Inspire Medical Systems, Inc. (NYSE:INSP)

Sivik Global Healthcare LLC acquired a new position in shares of Inspire Medical Systems, Inc. (NYSE:INSP - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 27,500 shares of the company's stock, valued at approximately $5,594,000. Inspire Medical Systems makes up 2.3% of Sivik Global Healthcare LLC's holdings, making the stock its 24th largest position. Sivik Global Healthcare LLC owned about 0.09% of Inspire Medical Systems as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently bought and sold shares of INSP. McGlone Suttner Wealth Management Inc. acquired a new position in shares of Inspire Medical Systems during the fourth quarter worth about $27,000. NBC Securities Inc. bought a new stake in shares of Inspire Medical Systems in the third quarter valued at approximately $34,000. RiverPark Advisors LLC acquired a new stake in Inspire Medical Systems during the third quarter worth approximately $44,000. Headinvest LLC acquired a new position in Inspire Medical Systems in the third quarter valued at about $48,000. Finally, International Assets Investment Management LLC acquired a new position in shares of Inspire Medical Systems in the 4th quarter valued at approximately $166,000. Institutional investors own 94.91% of the company's stock.

Insider Activity at Inspire Medical Systems

In related news, insider Randy Ban sold 3,060 shares of Inspire Medical Systems stock in a transaction dated Tuesday, February 27th. The stock was sold at an average price of $182.01, for a total value of $556,950.60. Following the completion of the transaction, the insider now owns 3,029 shares in the company, valued at approximately $551,308.29. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, CFO Richard Buchholz sold 15,000 shares of the stock in a transaction that occurred on Wednesday, April 17th. The shares were sold at an average price of $230.03, for a total transaction of $3,450,450.00. Following the completion of the transaction, the chief financial officer now owns 28,271 shares of the company's stock, valued at approximately $6,503,178.13. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Randy Ban sold 3,060 shares of the company's stock in a transaction that occurred on Tuesday, February 27th. The stock was sold at an average price of $182.01, for a total transaction of $556,950.60. Following the sale, the insider now directly owns 3,029 shares in the company, valued at $551,308.29. The disclosure for this sale can be found here. Insiders have sold a total of 76,371 shares of company stock worth $15,664,278 over the last quarter. Insiders own 4.10% of the company's stock.

Inspire Medical Systems Stock Performance

NYSE:INSP traded down $1.95 during trading hours on Tuesday, reaching $241.66. The stock had a trading volume of 234,975 shares, compared to its average volume of 524,136. The company has a 50 day moving average price of $209.56 and a two-hundred day moving average price of $187.29. Inspire Medical Systems, Inc. has a 52 week low of $123.27 and a 52 week high of $330.00. The stock has a market capitalization of $7.32 billion, a PE ratio of -326.57 and a beta of 1.37.

Inspire Medical Systems (NYSE:INSP - Get Free Report) last released its quarterly earnings results on Tuesday, February 6th. The company reported $0.49 EPS for the quarter, topping analysts' consensus estimates of ($0.04) by $0.53. Inspire Medical Systems had a negative net margin of 3.39% and a negative return on equity of 3.93%. The firm had revenue of $192.51 million during the quarter, compared to analysts' expectations of $186.75 million. During the same period in the previous year, the company earned $0.10 EPS. The firm's revenue for the quarter was up 39.6% compared to the same quarter last year. Equities research analysts predict that Inspire Medical Systems, Inc. will post -0.35 EPS for the current year.

Analysts Set New Price Targets

INSP has been the topic of several recent research reports. Stifel Nicolaus reissued a "hold" rating and set a $210.00 price objective on shares of Inspire Medical Systems in a report on Tuesday, January 2nd. KeyCorp began coverage on Inspire Medical Systems in a research note on Tuesday, February 6th. They set an "overweight" rating and a $278.00 price target for the company. Royal Bank of Canada started coverage on shares of Inspire Medical Systems in a research report on Friday, April 19th. They set an "outperform" rating and a $285.00 target price on the stock. Truist Financial reiterated a "buy" rating and set a $280.00 target price on shares of Inspire Medical Systems in a research note on Wednesday, March 20th. Finally, Mizuho reissued a "buy" rating and issued a $250.00 target price on shares of Inspire Medical Systems in a research report on Wednesday, March 27th. Four analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat.com, Inspire Medical Systems presently has an average rating of "Moderate Buy" and an average target price of $272.20.

About Inspire Medical Systems

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.